COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Rating of “Buy” from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have received an average rating of “Buy” from the seven brokerages that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.67.

CMPS has been the subject of several research analyst reports. HC Wainwright decreased their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada lowered their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Finally, Maxim Group lowered their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st.

Insider Transactions at COMPASS Pathways

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the sale, the insider now directly owns 6,905,774 shares of the company’s stock, valued at approximately $41,779,932.70. This represents a 27.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.25% of the company’s stock.

Institutional Trading of COMPASS Pathways

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tidal Investments LLC lifted its holdings in COMPASS Pathways by 43.6% during the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after purchasing an additional 5,795 shares during the last quarter. AdvisorShares Investments LLC boosted its stake in shares of COMPASS Pathways by 13.5% in the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock valued at $362,000 after buying an additional 7,243 shares during the period. Franklin Resources Inc. grew its position in COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock worth $1,810,000 after buying an additional 12,599 shares in the last quarter. Blue Trust Inc. acquired a new position in COMPASS Pathways in the 2nd quarter valued at $81,000. Finally, Green Alpha Advisors LLC bought a new stake in shares of COMPASS Pathways during the 3rd quarter valued at $99,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Up 0.7 %

CMPS opened at $4.59 on Monday. COMPASS Pathways has a twelve month low of $4.05 and a twelve month high of $12.75. The firm has a market cap of $314.05 million, a PE ratio of -2.09 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm’s fifty day moving average is $5.63 and its two-hundred day moving average is $6.55.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same period in the prior year, the business earned ($0.67) EPS. Equities research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.